Literature DB >> 23568167

[Therapeutic options for autoimmune encephalomyelitis].

N Borisow1, H Prüss, F Paul.   

Abstract

Autoantibodies to neuronal tissue are becoming increasingly more important in the evaluation and classification of several neurological diseases, e.g. neuromyelitis optica, paraneoplastic syndromes of the central nervous system (CNS), stiff person syndrome or autoimmune epilepsy. As these disorders are rare, no evidence-based recommendations for therapy are available. Currently, immunomodulating or immunosuppressive drugs are administered in most cases. In paraneoplastic syndromes treatment of the underlying cancer is of considerable importance. This overview summarizes current experiences and recommendations in the treatment of autoimmune neurological disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23568167     DOI: 10.1007/s00115-012-3608-4

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  78 in total

1.  Lack of response to rituximab therapy in patients with neuromyelitis optica: true non-responders or insufficient treatment?

Authors:  Su-Hyun Kim; Ho Jin Kim
Journal:  J Neurol Sci       Date:  2012-05-26       Impact factor: 3.181

Review 2.  [Anti-NMDA-receptor encephalitis. An interdisciplinary clinical picture].

Authors:  H Prüss; J Dalmau; V Arolt; K-P Wandinger
Journal:  Nervenarzt       Date:  2010-04       Impact factor: 1.214

3.  Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica.

Authors:  C Costanzi; M Matiello; C F Lucchinetti; B G Weinshenker; S J Pittock; J Mandrekar; P Thapa; A McKeon
Journal:  Neurology       Date:  2011-08-03       Impact factor: 9.910

4.  No MRI evidence of cortical lesions in neuromyelitis optica.

Authors:  Massimiliano Calabrese; Mi Sun Oh; Alice Favaretto; Francesca Rinaldi; Valentina Poretto; Sara Alessio; Byung-Chul Lee; Kyung-Ho Yu; Hyeo-Il Ma; Paola Perini; Paolo Gallo
Journal:  Neurology       Date:  2012-09-19       Impact factor: 9.910

5.  Neuromyelitis optica treatment: analysis of 36 patients.

Authors:  Denis Bernardi Bichuetti; Enedina Maria Lobato de Oliveira; Daniel May Oliveira; Nilton Amorin de Souza; Alberto Alain Gabbai
Journal:  Arch Neurol       Date:  2010-09

6.  Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?

Authors:  Su-Hyun Kim; Woojun Kim; Xue Feng Li; In-Ja Jung; Ho Jin Kim
Journal:  Mult Scler       Date:  2012-02-21       Impact factor: 6.312

7.  Devic's neuromyelitis optica treated with intravenous gamma globulin (IVIG).

Authors:  Jacqueline Bakker; Luanne Metz
Journal:  Can J Neurol Sci       Date:  2004-05       Impact factor: 2.104

8.  Nineteen episodes of recurrent myelitis in a woman with neuromyelitis optica and systemic lupus erythematosus.

Authors:  Sajjad Nasir; Douglas A Kerr; Julius Birnbaum
Journal:  Arch Neurol       Date:  2009-09

9.  Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients.

Authors:  Anu Jacob; Brian G Weinshenker; Ivo Violich; Nancy McLinskey; Lauren Krupp; Robert J Fox; Dean M Wingerchuk; Mike Boggild; Cris S Constantinescu; Aaron Miller; Tracy De Angelis; Marcelo Matiello; Bruce A C Cree
Journal:  Arch Neurol       Date:  2008-09-08

10.  Imaging the visual pathway in neuromyelitis optica.

Authors:  Caspar F Pfueller; Friedemann Paul
Journal:  Mult Scler Int       Date:  2011-03-16
View more
  3 in total

1.  [Autoantibody-associated schizophreniform psychoses: pathophysiology, diagnostics, and treatment].

Authors:  Ludger Tebartz van Elst; Karl Bechter; Harald Prüss; Alkomiet Hasan; Jo Hann Steiner; Frank Leypoldt; Dominique Endres
Journal:  Nervenarzt       Date:  2019-07       Impact factor: 1.214

Review 2.  [Paraneoplastic neurological syndromes and autoimmune encephalitis].

Authors:  O Stich; S Rauer
Journal:  Nervenarzt       Date:  2014-04       Impact factor: 1.214

Review 3.  Autoimmune encephalitis as a differential diagnosis of schizophreniform psychosis: clinical symptomatology, pathophysiology, diagnostic approach, and therapeutic considerations.

Authors:  Dominique Endres; Frank Leypoldt; Karl Bechter; Alkomiet Hasan; Johann Steiner; Katharina Domschke; Klaus-Peter Wandinger; Peter Falkai; Volker Arolt; Oliver Stich; Sebastian Rauer; Harald Prüss; Ludger Tebartz van Elst
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-03-12       Impact factor: 5.270

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.